Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 23;11:6685. doi: 10.1038/s41598-021-86021-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Synergistic antiproliferative interaction between YHO-1701 and osimertinib in H1975 cells. (A) The antiproliferative effect of YHO-1701 and/or osimertinib was examined at 72 h of exposure. Dose–response curves of YHO-1701 and/or osimertinib in H1975 cells (left panel) and their CI versus fraction affected (Fa) plots (right panel) are shown. Significance was determined with Tukey’s test. ^†††p < 0.001 versus the osimertinib group. ^‡p < 0.05; ^‡‡p < 0.01; and ^‡‡‡p < 0.001 versus the YHO-1701 group. (B) Phosphorylation/activation patterns of relevant molecules on EGFR and STAT3 signaling pathways were assessed by western blotting. H1975 cells were left untreated or treated with YHO-1701 and/or osimertinib at the indicated doses for 24 h. The blots were probed with the respective primary antibodies. Images were cropped for clarity, and full-length blots are displayed in Supplementary Fig. S3.